Inspection Record

Blue Ridge Pharmacy and Compounding Center — FDA 483 Findings

US FDAInspected 2015-07-10Published 2024-01-17 9 findingsStability and storageAseptic processing and sterility assuranceProcess validationTraining and personnelDeviation, CAPA, and investigation

Inspectors Viviana MattaThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Stability and storage

There is no written testing program designed to assess the stability characteristics ofdrug products.

2Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

3Aseptic processing and sterility assurance

Procedures designed lo prevent microbiological contamination ofdrug producls purporting to be sterile are not established and followed.

4Aseptic processing and sterility assurance

Each batch ofdrug product purporting to be sterile and pyrogen-free is not laboratory tested to detennine conformance to such requirements.

5Process validation

Written production and process control procedures are not documented at the time ofperfonnance.

6Training and personnel

Clothing of personnel engaged in the processing ofdrug products is not appropriate for the duties they perform.

7Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

8Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile do not include adequate validation ofthe sterili7.ation process.

9Deviation, CAPA, and investigation

Written records are not made of investigations into the failure ofa batch or any of its components to meet specifications.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Blue Ridge Pharmacy and Compounding Center company profile — full history US FDA documents, 2024 Go to Findings search